SG11202108744WA - Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders - Google Patents
Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disordersInfo
- Publication number
- SG11202108744WA SG11202108744WA SG11202108744WA SG11202108744WA SG11202108744WA SG 11202108744W A SG11202108744W A SG 11202108744WA SG 11202108744W A SG11202108744W A SG 11202108744WA SG 11202108744W A SG11202108744W A SG 11202108744WA SG 11202108744W A SG11202108744W A SG 11202108744WA
- Authority
- SG
- Singapore
- Prior art keywords
- derivatives
- pkm2
- thieno
- pyrrole
- obesity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805040P | 2019-02-13 | 2019-02-13 | |
| PCT/US2020/017965 WO2020167976A1 (en) | 2019-02-13 | 2020-02-12 | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108744WA true SG11202108744WA (en) | 2021-09-29 |
Family
ID=69941460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108744WA SG11202108744WA (en) | 2019-02-13 | 2020-02-12 | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220127267A1 (en) |
| EP (1) | EP3924056A1 (en) |
| JP (1) | JP2022520090A (en) |
| KR (1) | KR20210128435A (en) |
| CN (1) | CN113646050A (en) |
| AU (1) | AU2020221837A1 (en) |
| BR (1) | BR112021015996A2 (en) |
| CA (1) | CA3129829A1 (en) |
| CO (1) | CO2021011919A2 (en) |
| IL (1) | IL285445A (en) |
| MA (1) | MA54948A (en) |
| MX (1) | MX2021009743A (en) |
| SG (1) | SG11202108744WA (en) |
| WO (1) | WO2020167976A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3668513T3 (en) | 2017-08-15 | 2022-01-10 | Agios Pharmaceuticals Inc | PYRUVAT CHINASE ACTIVITIES FOR USE IN THE TREATMENT OF BLOOD DISEASES |
| CA3183980A1 (en) * | 2020-07-21 | 2022-01-27 | The Regents Of The University Of Michigan | Compositions and methods for activating pyruvate kinase |
| WO2022170200A1 (en) | 2021-02-08 | 2022-08-11 | Global Blood Therapeutics, Inc. | 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease |
| WO2023052783A1 (en) | 2021-09-30 | 2023-04-06 | Sitryx Therapeutics Limited | Novel compounds |
| AR127584A1 (en) | 2021-11-05 | 2024-02-07 | Sitryx Therapeutics Ltd | NOVEL COMPOUNDS |
| WO2023118875A1 (en) | 2021-12-22 | 2023-06-29 | Sitryx Therapeutics Limited | Phthalazine derivatives as pyruvate kinase modulators |
| CN115487190A (en) * | 2022-11-01 | 2022-12-20 | 复旦大学附属中山医院 | Application of pyruvate kinase M2 activator in preparation of medicine for treating systemic lupus erythematosus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8841305B2 (en) * | 2008-10-09 | 2014-09-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of the human pyruvate kinase M2 receptor |
| UA107667C2 (en) | 2009-06-29 | 2015-02-10 | Аджиос Фармасьютікалз, Інк. | Medical compounds stimulating activity of pyruvate kinase m2, compositions on their basis and use in the treatment of cancer |
| WO2012151452A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use in therapy |
| BR112013028422B8 (en) * | 2011-05-03 | 2022-01-11 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
| ES2829374T3 (en) * | 2011-05-03 | 2021-05-31 | Agios Pharmaceuticals Inc | Use of pyruvate kinase activators to increase the lifespan of red blood cells and treat anemia |
| WO2014018851A1 (en) | 2012-07-26 | 2014-01-30 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
| DK3668513T3 (en) * | 2017-08-15 | 2022-01-10 | Agios Pharmaceuticals Inc | PYRUVAT CHINASE ACTIVITIES FOR USE IN THE TREATMENT OF BLOOD DISEASES |
-
2020
- 2020-02-12 EP EP20713430.5A patent/EP3924056A1/en not_active Withdrawn
- 2020-02-12 MX MX2021009743A patent/MX2021009743A/en unknown
- 2020-02-12 SG SG11202108744WA patent/SG11202108744WA/en unknown
- 2020-02-12 WO PCT/US2020/017965 patent/WO2020167976A1/en unknown
- 2020-02-12 MA MA054948A patent/MA54948A/en unknown
- 2020-02-12 CN CN202080027241.9A patent/CN113646050A/en active Pending
- 2020-02-12 CA CA3129829A patent/CA3129829A1/en active Pending
- 2020-02-12 US US17/429,073 patent/US20220127267A1/en active Pending
- 2020-02-12 KR KR1020217029380A patent/KR20210128435A/en not_active Application Discontinuation
- 2020-02-12 BR BR112021015996A patent/BR112021015996A2/en not_active IP Right Cessation
- 2020-02-12 JP JP2021547190A patent/JP2022520090A/en not_active Withdrawn
- 2020-02-12 AU AU2020221837A patent/AU2020221837A1/en not_active Abandoned
-
2021
- 2021-08-08 IL IL285445A patent/IL285445A/en unknown
- 2021-09-10 CO CONC2021/0011919A patent/CO2021011919A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3129829A1 (en) | 2020-08-20 |
| MX2021009743A (en) | 2021-11-12 |
| AU2020221837A1 (en) | 2021-09-02 |
| CO2021011919A2 (en) | 2021-12-10 |
| WO2020167976A1 (en) | 2020-08-20 |
| KR20210128435A (en) | 2021-10-26 |
| JP2022520090A (en) | 2022-03-28 |
| BR112021015996A2 (en) | 2021-11-09 |
| EP3924056A1 (en) | 2021-12-22 |
| CN113646050A (en) | 2021-11-12 |
| IL285445A (en) | 2021-09-30 |
| MA54948A (en) | 2021-12-22 |
| US20220127267A1 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285445A (en) | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders | |
| PH12019500776A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| SA519401541B1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| EP3618829A4 (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| SI2430022T1 (en) | 1,2,4-TriazoloŠ4,3-aĆpyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders | |
| EP2170062A4 (en) | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders | |
| IL286180A (en) | Heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders | |
| WO2012156018A8 (en) | Antibodies for treatment of cancer expressing claudin 6 | |
| EP3950686A4 (en) | N-heteroaromatic amide derivatives for treatment of cancer | |
| HUE063367T2 (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| EP3634417A4 (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| EP3831412A4 (en) | Treatment of metastatic brain tumor by administration of antibody-drug conjugate | |
| EP2224919A4 (en) | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders | |
| IL275781A (en) | 1, 3, 4, 5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer's disease | |
| EP3573616A4 (en) | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders | |
| SG11202100126QA (en) | 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer | |
| AU2017264839A1 (en) | 2-Anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| EP2978422A4 (en) | Lipidic furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders | |
| IL279654A (en) | Pyrrolo[1,2-b] pyridazine derivatives | |
| WO2019113174A8 (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| EP3710005B8 (en) | SUBSTITUTED PYRROLO[2,1,-ALPHA]PHTHALAZINES AND BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINES AND THEIR USES IN THE TREATMENT OF CANCER | |
| FI4028017T3 (en) | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune diseases | |
| EP3705495A4 (en) | Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same | |
| IL283823A (en) | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease | |
| AU2022374702A1 (en) | Benzo[h]quinazoline-4-amine derivatives for the treatment of cancer |